 Shawn McCandless
Concepts (396)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 12 | 2020 | 179 | 2.210 |
Why?
| | Prader-Willi Syndrome | 8 | 2024 | 33 | 2.060 |
Why?
| | Urea Cycle Disorders, Inborn | 16 | 2020 | 26 | 1.910 |
Why?
| | Phenylbutyrates | 12 | 2020 | 23 | 1.180 |
Why?
| | Metabolism, Inborn Errors | 6 | 2021 | 42 | 1.050 |
Why?
| | Glycerol | 11 | 2020 | 90 | 1.050 |
Why?
| | Hyperphagia | 4 | 2024 | 38 | 0.810 |
Why?
| | Abnormalities, Multiple | 6 | 2013 | 197 | 0.780 |
Why?
| | Phenylketonurias | 3 | 2023 | 15 | 0.730 |
Why?
| | Ammonia | 9 | 2020 | 61 | 0.710 |
Why?
| | Glutamine | 9 | 2018 | 109 | 0.630 |
Why?
| | Infant, Newborn | 28 | 2022 | 6435 | 0.610 |
Why?
| | Chromosome Deletion | 4 | 2010 | 126 | 0.580 |
Why?
| | Galactosemias | 1 | 2019 | 16 | 0.570 |
Why?
| | Cinnamates | 1 | 2017 | 12 | 0.520 |
Why?
| | Aminopeptidases | 1 | 2017 | 20 | 0.520 |
Why?
| | Cyclohexanes | 1 | 2017 | 22 | 0.520 |
Why?
| | Appetite Depressants | 1 | 2017 | 19 | 0.520 |
Why?
| | Epoxy Compounds | 1 | 2017 | 31 | 0.520 |
Why?
| | Sesquiterpenes | 1 | 2017 | 52 | 0.510 |
Why?
| | Protease Inhibitors | 1 | 2017 | 102 | 0.500 |
Why?
| | Acidosis | 1 | 2017 | 105 | 0.490 |
Why?
| | Genetic Testing | 4 | 2023 | 480 | 0.470 |
Why?
| | Lysosomal Storage Diseases | 1 | 2015 | 5 | 0.460 |
Why?
| | Glycoproteins | 1 | 2017 | 354 | 0.450 |
Why?
| | Glycogen Storage Disease Type I | 2 | 2026 | 10 | 0.430 |
Why?
| | Public Health | 1 | 2020 | 571 | 0.430 |
Why?
| | Hyperammonemia | 4 | 2020 | 17 | 0.430 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 102 | 0.410 |
Why?
| | Infant | 25 | 2024 | 10060 | 0.400 |
Why?
| | Consanguinity | 1 | 2013 | 49 | 0.390 |
Why?
| | Hazardous Substances | 1 | 2012 | 16 | 0.370 |
Why?
| | Lipid Metabolism, Inborn Errors | 1 | 2012 | 20 | 0.370 |
Why?
| | Child, Preschool | 27 | 2024 | 11835 | 0.370 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 749 | 0.350 |
Why?
| | Obesity | 2 | 2017 | 3097 | 0.340 |
Why?
| | Amino Acids | 1 | 2015 | 519 | 0.330 |
Why?
| | Humans | 73 | 2026 | 145140 | 0.320 |
Why?
| | Phenylalanine | 4 | 2023 | 69 | 0.310 |
Why?
| | Child | 31 | 2026 | 22670 | 0.300 |
Why?
| | Rare Diseases | 5 | 2019 | 116 | 0.300 |
Why?
| | Phenylacetates | 4 | 2020 | 10 | 0.270 |
Why?
| | Adolescent | 23 | 2026 | 22479 | 0.260 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1186 | 0.250 |
Why?
| | Acyl-CoA Dehydrogenases | 2 | 2024 | 12 | 0.250 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2136 | 0.250 |
Why?
| | Glucose-6-Phosphatase | 1 | 2026 | 32 | 0.250 |
Why?
| | Feeding Behavior | 1 | 2012 | 689 | 0.240 |
Why?
| | Young Adult | 16 | 2026 | 14176 | 0.240 |
Why?
| | Male | 41 | 2026 | 72664 | 0.240 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 46 | 0.230 |
Why?
| | Female | 43 | 2026 | 78636 | 0.230 |
Why?
| | Dependovirus | 1 | 2026 | 78 | 0.230 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2005 | 43 | 0.220 |
Why?
| | Infant Formula | 2 | 2018 | 71 | 0.220 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.210 |
Why?
| | Mutation | 8 | 2019 | 4071 | 0.210 |
Why?
| | Methionine | 2 | 2021 | 161 | 0.210 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.210 |
Why?
| | Genetic Therapy | 1 | 2026 | 315 | 0.210 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
| | Diazoxide | 1 | 2024 | 21 | 0.210 |
Why?
| | Trisomy | 1 | 2005 | 78 | 0.200 |
Why?
| | False Positive Reactions | 2 | 2015 | 123 | 0.200 |
Why?
| | Neutropenia | 2 | 2022 | 154 | 0.200 |
Why?
| | Niacinamide | 1 | 2024 | 87 | 0.200 |
Why?
| | Growth Disorders | 2 | 2019 | 88 | 0.200 |
Why?
| | Genetic Diseases, Inborn | 1 | 2003 | 45 | 0.200 |
Why?
| | Vitamin B 12 | 2 | 2021 | 135 | 0.200 |
Why?
| | Double-Blind Method | 5 | 2026 | 2057 | 0.190 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 187 | 0.190 |
Why?
| | Face | 2 | 2020 | 174 | 0.190 |
Why?
| | Mass Spectrometry | 3 | 2004 | 728 | 0.180 |
Why?
| | Phenotype | 7 | 2019 | 3138 | 0.180 |
Why?
| | Leukodystrophy, Metachromatic | 1 | 2001 | 4 | 0.170 |
Why?
| | Cost of Illness | 1 | 2003 | 324 | 0.170 |
Why?
| | Metabolism | 1 | 2021 | 44 | 0.170 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2000 | 18 | 0.160 |
Why?
| | Strabismus | 1 | 2021 | 71 | 0.160 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2021 | 25 | 0.160 |
Why?
| | Acyl-CoA Dehydrogenase | 3 | 2012 | 8 | 0.160 |
Why?
| | Prenatal Care | 1 | 2023 | 309 | 0.160 |
Why?
| | Cardiomyopathies | 1 | 2024 | 335 | 0.160 |
Why?
| | Adult | 19 | 2026 | 40665 | 0.160 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 557 | 0.150 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.150 |
Why?
| | Alleles | 3 | 2019 | 888 | 0.150 |
Why?
| | Mental Status and Dementia Tests | 1 | 2019 | 26 | 0.150 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2019 | 80 | 0.140 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 33 | 0.140 |
Why?
| | DNA Polymerase II | 1 | 2018 | 35 | 0.140 |
Why?
| | Osteochondrodysplasias | 1 | 2018 | 18 | 0.140 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 427 | 0.140 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 79 | 0.140 |
Why?
| | Skin Abnormalities | 1 | 1998 | 12 | 0.140 |
Why?
| | Eye Abnormalities | 1 | 1998 | 17 | 0.140 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1995 | 0.140 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 31 | 0.140 |
Why?
| | Goldenhar Syndrome | 1 | 1998 | 11 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1506 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 804 | 0.140 |
Why?
| | Fructose Intolerance | 1 | 2018 | 5 | 0.140 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2018 | 10 | 0.140 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1998 | 48 | 0.140 |
Why?
| | Exome | 1 | 2019 | 227 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2018 | 85 | 0.140 |
Why?
| | Registries | 4 | 2021 | 2401 | 0.130 |
Why?
| | Prodrugs | 1 | 2018 | 52 | 0.130 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 71 | 0.130 |
Why?
| | Lipase | 1 | 2018 | 75 | 0.130 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2017 | 9 | 0.130 |
Why?
| | Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2017 | 6 | 0.130 |
Why?
| | Methionyl Aminopeptidases | 1 | 2017 | 1 | 0.130 |
Why?
| | Enzyme Assays | 1 | 2017 | 25 | 0.130 |
Why?
| | Early Termination of Clinical Trials | 1 | 2017 | 18 | 0.130 |
Why?
| | Pediatricians | 1 | 2019 | 121 | 0.130 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 79 | 0.130 |
Why?
| | Ketones | 1 | 2017 | 50 | 0.130 |
Why?
| | Syndrome | 4 | 2020 | 380 | 0.120 |
Why?
| | Glutaryl-CoA Dehydrogenase | 1 | 2016 | 5 | 0.120 |
Why?
| | Brain Diseases, Metabolic | 1 | 2016 | 8 | 0.120 |
Why?
| | Parents | 3 | 2020 | 1401 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 138 | 0.120 |
Why?
| | Body Mass Index | 2 | 2017 | 2437 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 582 | 0.120 |
Why?
| | Indians, North American | 1 | 2001 | 598 | 0.120 |
Why?
| | Patient Preference | 1 | 2018 | 223 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2115 | 0.110 |
Why?
| | Cross-Over Studies | 4 | 2026 | 608 | 0.110 |
Why?
| | Prevalence | 2 | 2012 | 2855 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2017 | 195 | 0.110 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2015 | 75 | 0.110 |
Why?
| | United States | 6 | 2020 | 16065 | 0.110 |
Why?
| | Cognition | 2 | 2023 | 1262 | 0.110 |
Why?
| | Mosaicism | 2 | 2005 | 73 | 0.110 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2013 | 9 | 0.100 |
Why?
| | Biomarkers | 4 | 2024 | 4282 | 0.100 |
Why?
| | Genetic Counseling | 1 | 2014 | 80 | 0.100 |
Why?
| | Hepatic Encephalopathy | 1 | 2013 | 25 | 0.100 |
Why?
| | Genotype | 1 | 2019 | 1844 | 0.100 |
Why?
| | Fibroblasts | 2 | 2017 | 1022 | 0.100 |
Why?
| | Rape | 1 | 2013 | 35 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2026 | 0.090 |
Why?
| | Cohort Studies | 3 | 2024 | 5988 | 0.090 |
Why?
| | Fetal Growth Retardation | 1 | 2018 | 592 | 0.090 |
Why?
| | Ubiquinone | 1 | 2012 | 35 | 0.090 |
Why?
| | Siblings | 1 | 2013 | 196 | 0.090 |
Why?
| | Drug Substitution | 1 | 2013 | 63 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 92 | 0.090 |
Why?
| | Intellectual Disability | 3 | 2019 | 178 | 0.090 |
Why?
| | Carnitine | 2 | 2003 | 91 | 0.090 |
Why?
| | Weight Loss | 1 | 2017 | 845 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2928 | 0.080 |
Why?
| | Urinary Tract | 1 | 1991 | 47 | 0.080 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2010 | 27 | 0.080 |
Why?
| | Ectodermal Dysplasia | 1 | 2010 | 20 | 0.080 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2021 | 18 | 0.080 |
Why?
| | Self Report | 1 | 2015 | 867 | 0.080 |
Why?
| | Diseases in Twins | 1 | 1991 | 115 | 0.080 |
Why?
| | Homocysteine | 2 | 2021 | 152 | 0.080 |
Why?
| | Diaphragm | 1 | 2010 | 48 | 0.080 |
Why?
| | Infant, Premature | 1 | 2015 | 619 | 0.080 |
Why?
| | Vaginal Diseases | 1 | 2010 | 19 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 6055 | 0.080 |
Why?
| | Risk | 1 | 2012 | 916 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2010 | 17 | 0.080 |
Why?
| | Heart Defects, Congenital | 3 | 2010 | 904 | 0.070 |
Why?
| | Caregivers | 1 | 2018 | 1070 | 0.070 |
Why?
| | Algorithms | 1 | 2017 | 1845 | 0.070 |
Why?
| | alpha-Glucosidases | 1 | 2009 | 9 | 0.070 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2009 | 6 | 0.070 |
Why?
| | Liver | 3 | 2013 | 1893 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 112 | 0.070 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.070 |
Why?
| | Mental Disorders | 1 | 1998 | 1154 | 0.070 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 206 | 0.070 |
Why?
| | Middle Aged | 10 | 2021 | 36126 | 0.070 |
Why?
| | Gene Frequency | 2 | 2016 | 484 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5411 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2010 | 295 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 609 | 0.060 |
Why?
| | Iduronate Sulfatase | 1 | 2006 | 2 | 0.060 |
Why?
| | Mucopolysaccharidosis II | 1 | 2006 | 2 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 326 | 0.060 |
Why?
| | Cooperative Behavior | 1 | 2010 | 461 | 0.060 |
Why?
| | Starch | 1 | 2026 | 22 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 323 | 0.060 |
Why?
| | Sex Factors | 1 | 2012 | 2099 | 0.060 |
Why?
| | Time Factors | 2 | 2015 | 7107 | 0.060 |
Why?
| | Brain | 1 | 1998 | 2934 | 0.060 |
Why?
| | Muscle, Skeletal | 2 | 2013 | 1789 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 647 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 174 | 0.060 |
Why?
| | Genetic Vectors | 1 | 2026 | 335 | 0.050 |
Why?
| | Karyotyping | 1 | 2005 | 105 | 0.050 |
Why?
| | Chromosome Disorders | 1 | 2005 | 47 | 0.050 |
Why?
| | Diet | 1 | 2012 | 1277 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2022 | 17247 | 0.050 |
Why?
| | Fragile X Syndrome | 1 | 2005 | 119 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2010 | 305 | 0.050 |
Why?
| | Disease Management | 2 | 2019 | 651 | 0.050 |
Why?
| | Radiography | 2 | 2010 | 852 | 0.050 |
Why?
| | Microcephaly | 1 | 2005 | 104 | 0.050 |
Why?
| | Gene Deletion | 1 | 2005 | 391 | 0.050 |
Why?
| | Lymphocytes | 3 | 2017 | 376 | 0.050 |
Why?
| | X Chromosome | 2 | 2000 | 65 | 0.050 |
Why?
| | Heterozygote | 2 | 2001 | 312 | 0.050 |
Why?
| | Anxiety | 2 | 2023 | 1117 | 0.050 |
Why?
| | Neuropsychological Tests | 3 | 2019 | 1134 | 0.050 |
Why?
| | Pregnancy | 4 | 2023 | 7182 | 0.050 |
Why?
| | Hyperhomocysteinemia | 1 | 2003 | 26 | 0.050 |
Why?
| | Carbon-Carbon Ligases | 1 | 2003 | 2 | 0.050 |
Why?
| | Food, Fortified | 1 | 2003 | 44 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 261 | 0.050 |
Why?
| | Cough | 2 | 2017 | 123 | 0.050 |
Why?
| | Pedigree | 2 | 2001 | 515 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 396 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 3194 | 0.050 |
Why?
| | Oxytocin | 1 | 2023 | 51 | 0.050 |
Why?
| | Infant Food | 1 | 2003 | 69 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 523 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 90 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2026 | 11741 | 0.040 |
Why?
| | Glucosides | 1 | 2022 | 55 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2005 | 281 | 0.040 |
Why?
| | Founder Effect | 1 | 2001 | 13 | 0.040 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 80 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 589 | 0.040 |
Why?
| | Homozygote | 2 | 2018 | 199 | 0.040 |
Why?
| | Workflow | 1 | 2023 | 183 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2005 | 447 | 0.040 |
Why?
| | History, 19th Century | 1 | 2001 | 63 | 0.040 |
Why?
| | United States Indian Health Service | 1 | 2001 | 45 | 0.040 |
Why?
| | Hand Deformities, Congenital | 1 | 2000 | 10 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2000 | 26 | 0.040 |
Why?
| | Facies | 1 | 2000 | 22 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 39 | 0.040 |
Why?
| | Warfare | 1 | 2001 | 98 | 0.040 |
Why?
| | Betaine | 1 | 2000 | 67 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 171 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 251 | 0.040 |
Why?
| | Methyltransferases | 1 | 2000 | 75 | 0.040 |
Why?
| | History, 20th Century | 1 | 2001 | 327 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 182 | 0.040 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2001 | 335 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2019 | 44 | 0.040 |
Why?
| | Drug Industry | 1 | 2019 | 49 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2821 | 0.040 |
Why?
| | Angelman Syndrome | 1 | 1999 | 11 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2018 | 5 | 0.040 |
Why?
| | Genomic Imprinting | 1 | 1999 | 26 | 0.040 |
Why?
| | Adrenoleukodystrophy | 1 | 1999 | 9 | 0.040 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2019 | 7 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 554 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 307 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 147 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1999 | 56 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2915 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5886 | 0.030 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.030 |
Why?
| | Urea | 1 | 2019 | 85 | 0.030 |
Why?
| | Executive Function | 1 | 2023 | 469 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 100 | 0.030 |
Why?
| | Canada | 1 | 2019 | 429 | 0.030 |
Why?
| | North America | 1 | 2019 | 301 | 0.030 |
Why?
| | Nitrogen | 1 | 2018 | 125 | 0.030 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2017 | 10 | 0.030 |
Why?
| | Europe | 1 | 2019 | 416 | 0.030 |
Why?
| | Length of Stay | 1 | 2003 | 1348 | 0.030 |
Why?
| | Cleft Lip | 1 | 1998 | 72 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 1997 | 302 | 0.030 |
Why?
| | Biochemistry | 1 | 2017 | 36 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1185 | 0.030 |
Why?
| | Cleft Palate | 1 | 1998 | 90 | 0.030 |
Why?
| | Skull | 1 | 1998 | 161 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1998 | 118 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2006 | 1368 | 0.030 |
Why?
| | DNA Replication | 1 | 2018 | 249 | 0.030 |
Why?
| | Glutarates | 1 | 2016 | 11 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 466 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 441 | 0.030 |
Why?
| | Cocaine | 1 | 1998 | 161 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 403 | 0.030 |
Why?
| | Lipids | 1 | 2021 | 706 | 0.030 |
Why?
| | Fever | 1 | 2017 | 318 | 0.030 |
Why?
| | Child Behavior | 1 | 1998 | 236 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 8035 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1048 | 0.030 |
Why?
| | Cognition Disorders | 1 | 1999 | 539 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1703 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 669 | 0.030 |
Why?
| | North Carolina | 2 | 2006 | 129 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 276 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2881 | 0.030 |
Why?
| | Primary Health Care | 1 | 2004 | 1725 | 0.020 |
Why?
| | Immunoglobulin G | 2 | 2009 | 887 | 0.020 |
Why?
| | Enzyme Stability | 2 | 2004 | 73 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 571 | 0.020 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1998 | 600 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1121 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 407 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 376 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2019 | 826 | 0.020 |
Why?
| | DNA | 2 | 2010 | 1433 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 1991 | 18 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1731 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1998 | 836 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2010 | 20 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2010 | 19 | 0.020 |
Why?
| | Chromosome Breakage | 1 | 2010 | 23 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 28 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3338 | 0.020 |
Why?
| | Muscle Hypotonia | 1 | 2010 | 33 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1991 | 133 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 781 | 0.020 |
Why?
| | Colpotomy | 1 | 2010 | 2 | 0.020 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 55 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 238 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4142 | 0.020 |
Why?
| | Glycogen | 1 | 2009 | 55 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4310 | 0.020 |
Why?
| | Tracheostomy | 1 | 2010 | 142 | 0.020 |
Why?
| | Escherichia coli | 2 | 2004 | 834 | 0.020 |
Why?
| | Pilot Projects | 2 | 2006 | 1889 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 201 | 0.020 |
Why?
| | Vagina | 1 | 2010 | 202 | 0.020 |
Why?
| | Skin Diseases | 1 | 2009 | 152 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1742 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 847 | 0.020 |
Why?
| | Aged | 2 | 2018 | 26096 | 0.020 |
Why?
| | Glycosaminoglycans | 1 | 2006 | 79 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 968 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1132 | 0.010 |
Why?
| | False Negative Reactions | 1 | 2006 | 61 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8318 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 2006 | 37 | 0.010 |
Why?
| | Biomedical Research | 1 | 2012 | 717 | 0.010 |
Why?
| | Joints | 1 | 2006 | 106 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 428 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 84 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2010 | 713 | 0.010 |
Why?
| | Myristic Acid | 1 | 2004 | 10 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2006 | 543 | 0.010 |
Why?
| | Body Weight | 1 | 2009 | 969 | 0.010 |
Why?
| | Safety | 1 | 2006 | 357 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 507 | 0.010 |
Why?
| | Histidine | 1 | 2004 | 66 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2004 | 151 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2004 | 70 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2207 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 217 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 302 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 563 | 0.010 |
Why?
| | Acids | 1 | 2003 | 17 | 0.010 |
Why?
| | Brain Edema | 1 | 2003 | 62 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 457 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2004 | 255 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2949 | 0.010 |
Why?
| | Lysine | 1 | 2004 | 304 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2168 | 0.010 |
Why?
| | Chaperonin 10 | 1 | 2001 | 2 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2001 | 12 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2003 | 159 | 0.010 |
Why?
| | Prion Proteins | 1 | 2000 | 5 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2000 | 28 | 0.010 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2000 | 9 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2000 | 59 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 1066 | 0.010 |
Why?
| | Prions | 1 | 2000 | 50 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 387 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 136 | 0.010 |
Why?
| | Exons | 1 | 2001 | 363 | 0.010 |
Why?
| | Amyloid | 1 | 2000 | 94 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 276 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 504 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 498 | 0.010 |
Why?
| | Models, Molecular | 1 | 2004 | 1597 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1999 | 61 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1999 | 190 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 271 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 632 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2900 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 776 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2127 | 0.010 |
Why?
| | Social Behavior | 1 | 1999 | 284 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1039 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5582 | 0.010 |
Why?
| | Animals | 3 | 2004 | 37952 | 0.010 |
Why?
| | DNA Methylation | 1 | 1999 | 667 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3410 | 0.010 |
Why?
| | Genetic Variation | 1 | 1997 | 967 | 0.010 |
Why?
| | Mice | 2 | 2000 | 18303 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2857 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 3892 | 0.000 |
Why?
|
|
McCandless's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|